Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.62 |
| ▸ | PDE8A | O60658 | 1/20 | 0.62 |
| ▸ | PDE9A | O76083 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | PDE6A | P16499 | 1/20 | 0.62 |
| ▸ | PDE6G | P18545 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lodenafil SCHEMBL18416781 | 0.91 | PDE5A (0.78) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL19254528 | 0.90 | PDE5A (0.78) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| Sildenafil SCHEMBL492566 | 0.89 | PDE5A (0.77) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Lodenafil Carbonate SCHEMBL5008159 | 0.89 | PDE5A (0.84) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| Lodenafil Carbonate SCHEMBL30852274 | 0.89 | PDE5A (0.84) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL21705397 | 0.87 | PDE5A (0.79) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL19518061 | 0.86 | PDE5A (0.77) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL12988694 | 0.84 | PDE5A (0.58) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| SCHEMBL16558010 | 0.84 | PDE5A (0.70) | PDE5APDE3BPDE3AHDAC1HDAC6 | |
| Iodide SCHEMBL12989833 | 0.84 | PDE5A (0.58) | PDE5APDE3BPDE3AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190008870-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | JANSFAT BIOTECHNOLOGY CO LTD (TW) | 2019-01-10 | — | — | US | disclosed |
| US-20180078559-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY COPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3267986-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | Indiana University Research&Technology Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3241552-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | Jansfat Biotechnology Co., Ltd. (TW) | 2017-11-08 | — | — | EP | disclosed |
| US-20170312286-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2017-11-02 | — | — | US | disclosed |
| WO-2016149218-A1 | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312286-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | GYS2, PYGL, GYS1 | PDE5A 14/4885PDE3B 78/4885PDE3A 69/4885 |
| US-20190008870-A1 | COMPOSITIONS AND METHODS FOR LIPID METABOLISM DISORDER | GYS2, PYGL, GYS1 | PDE5A 14/4885PDE3B 78/4885PDE3A 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.